The pharmaceutical company Molypharma, whose activities include the manufacture, preparation and commercialisation of PET radiopharmaceuticals and CIC biomaGUNE, have signed a strategic agreement that includes, amongst other aspects, authorisation for the former to use and exploit the cyclotron and radiopharmaceutical facilities at CIC biomaGUNE's Molecular Imaging Unit to produce commercial PET radiopharmaceuticals. Molypharma has a Pharmaceutical Marketing Authorisation in Spain for the injectable solution fludeoxyglucose (18F), or FDG, which is currently the most widely used PET radiopharmaceutical. The company has successfully passed the mandated inspection by the health authorities in order to obtain the authorisation required to undertake its activities.

In this way, CIC biomaGUNE, establishes a link with a potential partner company for the development of new tracers, one of the key research lines of the centre and its Molecular Imaging Unit, the only Singular Scientific-Technological Facility (ICTS, in Spanish) in the Basque Country.

The company will supply the PET radiopharmaceuticals produced at the CIC biomaGUNE facility to public and private hospitals in the Basque Country.